logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5447.produswest2
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5447.produswest2
World TB Day 2022—Progress on tools and care models amid global setbacks from Covid-19 | Collections | MSF Science Portal
World TB Day 2022—Progress on tools and care models amid global setbacks from Covid-19

World TB Day 2022—Progress on tools and care models amid global setbacks from Covid-19

Collection Content

Journal Article
|
Research

Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs

Huerga H, Khan UT, Bastard M, Mitnick CD, Lachenal N,  et al.
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND
Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...
Journal Article
|
Research

Whole genome sequencing has the potential to improve treatment for rifampicin-resistant tuberculosis in high burden settings: a retrospective cohort study

Cox HS, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A,  et al.
2022-02-16 • Journal of Clinical Microbiology
2022-02-16 • Journal of Clinical Microbiology
BACKGROUND
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely...
Journal Article
|
Research

Person-centred care and short oral treatment for rifampicin-resistant tuberculosis improve retention in care in Kandahar, Afghanistan

Mesic A, Ishaq S, Khan WH, Mureed A, Mar HT,  et al.
2022-01-03 • Tropical Medicine and International Health
2022-01-03 • Tropical Medicine and International Health
OBJECTIVES
To describe the effect of adaptations to a person-centred care with short oral regimens on retention in care for rifampicin-resistant TB (RR-TB) in Kandahar province, Afgh...
Journal Article
|
Letter

Urine LAM diagnostics can close the deadly testing gap for TB

Deborggraeve S, Menghaney L, Lynch S, McKenna L, Branigan D
2021-10-01 • International Journal of Tuberculosis and Lung Disease
2021-10-01 • International Journal of Tuberculosis and Lung Disease
Journal Article
|
Letter

TB research requires strong protections, innovation, and increased funding in response to COVID-19

Nyang'wa BT, LaHood AN, Mitnick CD, Guglielmetti L
2021-05-29 • Trials
2021-05-29 • Trials
When 2020 opened, approximately 11 million new tuberculosis (TB) cases and nearly 1.5 million TB-related deaths were predicted during the year. And, the gap between required and availabl...
Conference Material
|
Abstract

Early termination of randomisation into TB-PRACTECAL, a study examining novel six month, all-oral regimens for treatment of drug-resistant tuberculosis

Nyang'wa BT, Berry C, Motta I, Kazounis E
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
INTRODUCTION
Almost 500,000 people worldwide develop multidrug-resistant tuberculosis (MDR-TB) annually, with a treatment success rate of around 60%. Current treatment consists of up...
Conference Material
|
Video

Early termination of randomisation into TB-PRACTECAL, a study examining novel six month, all-oral regimens for treatment of drug-resistant tuberculosis

Berry C
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
Journal Article
|
Letter

A positive COVID-19 test is associated with high mortality in RR-TB-HIV patients

Mohr-Holland E, Daniels J, Douglas-Jones B, Mema N, Scott V,  et al.
2021-05-01 • International Journal of Tuberculosis and Lung Disease
2021-05-01 • International Journal of Tuberculosis and Lung Disease
Journal Blog
|
Perspective

The TB community in 2021—tired, frustrated, but hopeful

Berry C
2021-03-24 • BMJ Opinion (blog)
2021-03-24 • BMJ Opinion (blog)
The TB community continues to tackle one of the world’s oldest epidemics while struggling with the newest one, writes Catherine Berry
Journal Article
|
Commentary

Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic

Mohr-Holland E, Douglas-Jones B, Apolisi I, Ngambu N, Mathee S,  et al.
2021-03-01 • Lancet Child and Adolescent Health
2021-03-01 • Lancet Child and Adolescent Health
Journal Article
|
Commentary

Introducing new and repurposed TB drugs: the endTB experience

Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...

See more collections

Mini-Lab—MSF's simplified bacteriology laboratory for low-resource settings
Mini-Lab—MSF's simplified bacteriology laboratory for low-res...
Resistance to antibiotics is a growing public health crisis, especially in countries with fragile health systems and in regions at war. One key limitation in most of these settings is a lack of clinical bacteriology laboratory capacity, which leaves medical providers without ways to accurately diagnose patient infections and to tailor antibiotic treatment accordingly. To help fill this critical gap, MSF and partners have developed the Mini-Lab—a small-scale, standalone lab that is easy to transport, set up and operate by staff after only a short training. Its six modules are stocked with everything needed to diagnose common bloodstream and urinary tract infections and to perform antibiotic sensitivity testing using methods adapted to extremely hot climates and remote settings. With Mini-Lab now being rolled out to selected MSF projects, here we highlight the background to its development and some of the research behind the bacteriological tests it incorporates.
MSF logo
Healthcare needs of older people in humanitarian settings

Globally, the number of older people is rapidly increasing, with those aged 60+ expected to more than double by 2050—yet in humanitarian crises, they remain one of the most neglected groups. Older adults often face higher risks due to chronic illnesses, mobility issues, and limited access to appropriate care, especially in low-resource or emergency settings. Despite these needs, humanitarian responses rarely prioritize them, and data on their health and mortality are often lacking.


This collection highlights some of MSF's work towards addressing this gap through targeted mental health support, care for older homeless populations, and operational research into barriers and needs. However, MSF also acknowledges major challenges remain, including inadequate age-specific services, data gaps, and the need for more geriatric expertise.


Watch this space for more publications from a Lancet Healthy Longevity series on healthcare rights and needs of older people.

MSF logo
Diphtheria
No description available
View All Collections